|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300069808 |
|
最近更新日期: Date of Last Refreshed on: |
2023-03-27 09:49:24 |
|
注册时间: Date of Registration: |
2023-03-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于VR虚拟现实干预模式对卵巢癌腹腔化疗患者焦虑与疼痛的效果研究 |
|
Public title: |
Effect of virtual reality based intervention model on anxiety and pain in patients with ovarian cancer undergoing intraperitoneal chemotherapy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于VR虚拟现实干预模式对卵巢癌腹腔化疗患者焦虑与疼痛的效果研究 |
|
Scientific title: |
Effect of virtual reality based intervention model on anxiety and pain in patients with ovarian cancer undergoing intraperitoneal chemotherapy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
毛文娟 |
研究负责人: |
陈文多 |
|
Applicant: |
Maowenjuan |
Study leader: |
chenwenduo |
|
申请注册联系人电话: Applicant telephone: |
18610601556 |
研究负责人电话:
Study leader's |
18600578992 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
maowenjuan@pkuih.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
chenwenduo@pkuih.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
昌平区中关村生命科学园生命园路一号北京大学国际医院妇科 |
研究负责人通讯地址: |
Department of Gynecology, Peking University International Hospital, No. 1, shengmingyuan Road, Zhongguancun Life Science Park, Changping District |
|
Applicant address: |
Department of Gynecology, Peking University International Hospital, No. 1, shengmingyuan Road, Zhongguancun Life Science Park, Changping District |
Study leader's address: |
昌平区中关村生命科学园生命园路一号北京大学国际医院 |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京大学国际医院 |
||
|
Applicant's institution: |
Peking University International Hospital |
||
|
研究负责人所在单位: |
北京大学国际医院 |
||
|
Affiliation of the Leader: |
Peking University International Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022-KY-0062-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京大学国际医院生物医学伦理委员会 |
||
|
Name of the ethic committee: |
Biomedical ethics committee of Peking University International Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-02-13 00:00:00 | ||
|
伦理委员会联系人: |
梁军 |
||
|
Contact Name of the ethic committee: |
Liang Jun |
||
|
伦理委员会联系地址: |
昌平区中关村生命科学园生命园路一号北京大学国际医院 |
||
|
Contact Address of the ethic committee: |
Peking University International Hospital, No. 1, shengmingyuan Road, Zhongguancun Life Science Park, Changping District |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
01069007608 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
liangjun@pkuih.edu.cn |
|
研究实施负责(组长)单位: |
北京大学国际医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Peking Universiy International Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
昌平区中关村生命科学园生命园路一号北京大学国际医院妇科 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Department of Gynecology, Peking University International Hospital, No. 1, shengmingyuan Road, Zhongguancun Life Science Park, Changping District |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
院内科研基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hospital Internal Medicine Research Fund |
||||||||||||||||||||||
|
研究疾病: |
卵巢癌腹腔化疗 |
||||||||||||||||||||||
|
Target disease: |
Intraperitoneal chemotherapy for ovarian cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探讨基于虚拟现实技术结合正念冥想应用于卵巢癌腹腔穿刺化疗患者,缓解患者焦虑、疼痛的效果研究。 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore the effect of virtual reality technology combined with mindfulness meditation on alleviating anxiety and pain in patients with ovarian cancer undergoing intraperitoneal puncture chemotherapy. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
纳入标准:(1)根据癌症患者的心理分期,选择“接受期”的癌症患者:18≥年龄≤60岁;(2)卵巢癌减灭术后,残留病灶<1cm;(3)经医生判断,腹腔化疗白细胞≥4.0×109/L、中性粒细胞数≥2.0×109/L、血小板≥8×109/L、肌酐清除率>50ml/min、转氨酶>100u/L,符合腹腔化疗的患者;(4)无严重的心脑血管疾病及其他并存疾病;(5)签署知情同意书,自愿配合完成临床研究者;(6)就诊前未接受过心理辅导和治疗;(7)有正常的中文沟通和理解能力;(8)生活自理能力量表:为完全自理,评分≥60-100分。 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion criteria: (1) According to the psychological stage of cancer patients, cancer patients with "acceptance period" were selected: 18≥ age ≤60 years old; (2) Residual lesions < 1cm after reduction of ovarian cancer; (3) According to the doctor's judgment, abdominal chemotherapy for white blood cells ≥4.0×109/L, neutrophil number ≥2.0×109/L, platelet ≥8×109/L, creatinine clearance > 50ml/min, transaminase > 100u/L, consistent with abdominal chemotherapy; (4) no serious cardiovascular and cerebrovascular diseases or other co-existing diseases; (5) Sign informed consent and voluntarily cooperate with clinical researchers; (6) have not received psychological counseling and treatment before seeing a doctor; (7) Have normal Chinese communication and understanding ability; (8) Self-care Ability Scale: complete self-care, score ≥60-100 points |
||||||||||||||||||||||
|
排除标准: |
排除标准:(1)面部或眼部有活动性感染或开放性伤口;(2)眼部疾患:视力障碍、青光眼、白内障、飞蚊症、视力缺陷;(3)对头戴式耳机和VR眼镜接触皮肤过敏者或眩晕者;(4)具有严重的听力障碍;(6)具有精神病史,如痴呆、恐高症、幽闭恐惧症、癫痫发作史等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria: (1) Active infection or open wound on face or eye; (2) Eye diseases: visual impairment, glaucoma, cataract, flying mosquito disease, visual defect; (3) People who are allergic to skin or dizzy due to contact with headphones and VR glasses; (4) Have serious hearing impairment; (6) Have a history of mental illness, such as dementia, acrophobia, claustrophobia, epilepsy, etc. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-08-01 00:00:00至 To 2024-08-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-03-27 00:00:00 至 To 2023-09-27 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
按计算机产生的随机数字表法将患者随机分为对照组和试验组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Patients were randomly divided into a control group and a trial group using a computer-generated random number table method |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Do not share |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集主要通过病例记录表完成,数据管理通过SPSS数据库管理完成 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection is mainly completed through case record form, and data management is completed through SPSS database management |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |